U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Microsatellite Stable Ovarian Carcinoma

MedGen UID:
1792731
•Concept ID:
C5556290
•
Neoplastic Process

Definition

Ovarian carcinoma characterized by the absence of microsatellite instability. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMicrosatellite Stable Ovarian Carcinoma

Professional guidelines

PubMed

Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, Chi DS, Weigelt B, Konner JA, Zamarin D
Int J Gynecol Cancer 2022 Aug 1;32(8):1017-1024. doi: 10.1136/ijgc-2022-003430. PMID: 35545291Free PMC Article
Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer.
Sood AK, Holmes R, Hendrix MJ, Buller RE
Cancer Res 2001 Jun 1;61(11):4371-4. PMID: 11389062

Recent clinical studies

Etiology

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Patel SP, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD, Carneiro BA
J Immunother Cancer 2024 Feb 2;12(2) doi: 10.1136/jitc-2023-007340. PMID: 38309722Free PMC Article
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, Chi DS, Weigelt B, Konner JA, Zamarin D
Int J Gynecol Cancer 2022 Aug 1;32(8):1017-1024. doi: 10.1136/ijgc-2022-003430. PMID: 35545291Free PMC Article
Risk factors for ovarian cancers with and without microsatellite instability.
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J
Int J Gynecol Cancer 2014 May;24(4):664-9. doi: 10.1097/IGC.0000000000000134. PMID: 24755492
Risk factors for ovarian cancers with and without microsatellite instability.
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J
Int J Gynecol Cancer 2013 Jul;23(6):1010-5. doi: 10.1097/IGC.0b013e31829a5527. PMID: 23748177Free PMC Article
Genetic classification of ovarian carcinoma based on microsatellite analysis: relationship to clinicopathological features and patient survival.
Huan Z, Nakayama K, Nakayama N, Ishibashi M, Yeasmin S, Katagiri A, Purwana IN, Iida K, Maruyama R, Fukumoto M, Miyazaki K
Oncol Rep 2008 Mar;19(3):775-81. PMID: 18288415

Diagnosis

Elucidation of genomic origin of synchronous endometrial and ovarian cancer (SEO) by genomic and microsatellite analysis.
Sakamoto I, Hirotsu Y, Amemiya K, Nozaki T, Mochizuki H, Omata M
J Gynecol Oncol 2023 Jan;34(1):e6. Epub 2022 Oct 6 doi: 10.3802/jgo.2023.34.e6. PMID: 36245225Free PMC Article
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
Sokol ES, Jin DX, Fine A, Trabucco SE, Maund S, Frampton G, Molinero L, Antonarakis ES
JCO Precis Oncol 2022 Jun;6:e2100531. doi: 10.1200/PO.21.00531. PMID: 35772050Free PMC Article
Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI, Killian JK, Venstrom JM, Ramkissoon SH, Ross JS, Elvin JA
Mod Pathol 2021 May;34(5):983-993. Epub 2020 Oct 19 doi: 10.1038/s41379-020-00699-1. PMID: 33077920
Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma.
Li L, Yue P, Song Q, Yen TT, Asaka S, Wang TL, Beavis AL, Fader AN, Jiao Y, Yuan G, Shih IM, Song Y
J Pathol 2021 Jan;253(1):119-128. Epub 2020 Nov 13 doi: 10.1002/path.5566. PMID: 33016334
Chromatin organisation and cancer prognosis: a pan-cancer study.
Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE
Lancet Oncol 2018 Mar;19(3):356-369. Epub 2018 Feb 3 doi: 10.1016/S1470-2045(17)30899-9. PMID: 29402700Free PMC Article

Therapy

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Patel SP, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD, Carneiro BA
J Immunother Cancer 2024 Feb 2;12(2) doi: 10.1136/jitc-2023-007340. PMID: 38309722Free PMC Article
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, Chi DS, Weigelt B, Konner JA, Zamarin D
Int J Gynecol Cancer 2022 Aug 1;32(8):1017-1024. doi: 10.1136/ijgc-2022-003430. PMID: 35545291Free PMC Article
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
Rahma OE, Tyan K, Giobbie-Hurder A, Brohl AS, Bedard PL, Renouf DJ, Sharon E, Streicher H, Hathaway E, Cunningham R, Manos M, Severgnini M, Rodig S, Stephen Hodi F
J Immunother Cancer 2022 Mar;10(3) doi: 10.1136/jitc-2021-003569. PMID: 35264434Free PMC Article
Optimizing immunotherapy for gynecologic cancers.
Rubinstein MM, Makker V
Curr Opin Obstet Gynecol 2020 Feb;32(1):1-8. doi: 10.1097/GCO.0000000000000603. PMID: 31833942Free PMC Article
Chromatin organisation and cancer prognosis: a pan-cancer study.
Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE
Lancet Oncol 2018 Mar;19(3):356-369. Epub 2018 Feb 3 doi: 10.1016/S1470-2045(17)30899-9. PMID: 29402700Free PMC Article

Prognosis

HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce SF, Wu S, Ribeiro JR, Farrell A, Oberley MJ, Winer I, Erickson BK, Klc T, Jones NL, Thaker PH, Powell MA
Gynecol Oncol 2023 May;172:98-105. Epub 2023 Mar 30 doi: 10.1016/j.ygyno.2023.03.008. PMID: 37003074
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, Chi DS, Weigelt B, Konner JA, Zamarin D
Int J Gynecol Cancer 2022 Aug 1;32(8):1017-1024. doi: 10.1136/ijgc-2022-003430. PMID: 35545291Free PMC Article
Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
Zeng H, Chen L, Zhang M, Luo Y, Ma X
Gynecol Oncol 2021 Oct;163(1):171-180. Epub 2021 Jul 16 doi: 10.1016/j.ygyno.2021.07.015. PMID: 34275655
Risk factors for ovarian cancers with and without microsatellite instability.
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Sun P, Narod SA, Schildkraut J
Int J Gynecol Cancer 2014 May;24(4):664-9. doi: 10.1097/IGC.0000000000000134. PMID: 24755492
Risk factors for ovarian cancers with and without microsatellite instability.
Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J
Int J Gynecol Cancer 2013 Jul;23(6):1010-5. doi: 10.1097/IGC.0b013e31829a5527. PMID: 23748177Free PMC Article

Clinical prediction guides

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
Patel SP, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD, Carneiro BA
J Immunother Cancer 2024 Feb 2;12(2) doi: 10.1136/jitc-2023-007340. PMID: 38309722Free PMC Article
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.
Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, Chi DS, Weigelt B, Konner JA, Zamarin D
Int J Gynecol Cancer 2022 Aug 1;32(8):1017-1024. doi: 10.1136/ijgc-2022-003430. PMID: 35545291Free PMC Article
Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
Zeng H, Chen L, Zhang M, Luo Y, Ma X
Gynecol Oncol 2021 Oct;163(1):171-180. Epub 2021 Jul 16 doi: 10.1016/j.ygyno.2021.07.015. PMID: 34275655
Chromatin organisation and cancer prognosis: a pan-cancer study.
Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE
Lancet Oncol 2018 Mar;19(3):356-369. Epub 2018 Feb 3 doi: 10.1016/S1470-2045(17)30899-9. PMID: 29402700Free PMC Article
Genetic classification of ovarian carcinoma based on microsatellite analysis: relationship to clinicopathological features and patient survival.
Huan Z, Nakayama K, Nakayama N, Ishibashi M, Yeasmin S, Katagiri A, Purwana IN, Iida K, Maruyama R, Fukumoto M, Miyazaki K
Oncol Rep 2008 Mar;19(3):775-81. PMID: 18288415

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...